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Abstract
Endemic Burkitt lymphoma (eBL) is an aggressive B cell cancer characterized by an IgH/c-myc translocation and the harbor-
ing of Epstein–Barr virus (EBV). Evidence accumulates that CD4 + T cells might contribute to eBL pathogenesis. Here, we 
investigate the presence of CD4 + T cells in primary eBL tissue and their potential dichotomous impact on an EBV-infected 
pre-eBL cell model using ex vivo material and in vitro co-cultures. In addition, we establish a novel method to study the 
effect of IgH/c-myc translocation in primary B cells by employing a CRISPR/Cas9 knock-in approach to introduce and tag 
de novo translocation. We unprecedently document that CD4 + T cells are present in primary eBL tumor tissue. Furthermore, 
we demonstrate that CD4 + T cells on the one hand suppress eBL development by killing pre-eBL cells lacking IgH/c-myc 
translocation in vitro and on the other hand indirectly promote eBL development by inducing crucial EBV Latency III to 
Latency I switching in pre-eBL cells. Finally, we show that while the mere presence of an IgH/c-myc translocation does 
not suffice to escape CD4 + T-cell-mediated killing in vitro, the CD4 + T-cell-mediated suppression of EBV’s Latency III 
program in vivo may allow cells harboring an IgH/c-myc translocation and additional mutations to evade immune control 
and proliferate by means of deregulated c-myc activity, resulting in neoplasia. Thus, our study highlights the dichotomous 
effects of CD4 + T cells and the mechanisms involved in eBL pathogenesis, suggests mechanisms of their impact on eBL 
progression, and provides a novel in vitro model for further investigation of IgH/c-myc translocation.
Keywords Epstein–Barr virus · T helper cells · Endemic Burkitt lymphoma · CRISPR/CAS9 · Latency III to Latency I 
switch · IgH/c-myc translocation
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EBV  Epstein–Barr virus
EdU  5-Ethynyl-2'-deoxyuridine
FISH  Fluorescence in situ hybridization
gDNA  Genomic DNA
GFP  Green fluorescent protein
IHC  Immunohistochemistry
LCL  Lymphoblastoid cell line
LMP  Latent membrane protein
LN  Lymph node
qRT-PCR  Quantitative real-time polymerase chain 
reaction
Tfh  Follicular T helper
TMC  Tonsillar mononuclear cell
Introduction
Endemic Burkitt lymphoma (eBL), the most frequent type 
of Burkitt lymphoma, is widespread in sub-Saharan Africa 
and affects mainly immunocompetent hosts [1]. eBL is 
thought to originate from germinal center (GC) B cells 
[2] and is characterized by the presence of an IgH/c-myc 
translocation, which leads to deregulated expression of the 
proto-oncogene c-myc [3]. The IgH/c-myc translocation is 
not sufficient for eBL development, suggesting a multi-step 
pathogenesis [4]. Additional factors, including mutations 
[5] and chronic immune-stimulating co-infections such as 
malaria [6], are required. Importantly, 98% of eBL tumors 
harbor Epstein–Barr virus (EBV) [6], though its pathogenic 
role is incompletely elucidated.
EBV is a B-lymphotropic virus which infects more than 
90% of the world’s population, usually with no ill effects 
[7]. Key for EBV persistence is its ability to evade the host’s 
immune response by entering latency in B cells. During 
early B cell infection, EBV is found in Latency III program. 
It transforms B cells into proliferating blasts and is depend-
ent on EBV nuclear antigen 2 (EBNA2) and latent mem-
brane protein 1 (LMP1) expression, as well as Cp promoter 
[8, 9]. In vitro, EBV-infected B cells remain in Latency III 
and proliferate almost indefinitely as lymphoblastoid cell 
lines (LCLs). In immunocompetent hosts, however, the 
immune response drives transition from Latency III to the 
more restricted latency programs II, I, or 0 [10], since the 
Latency III program is highly immunogenic [11, 12]. Thus, 
the vast majority of EBV-infected B cells in vivo are found 
in Latency I/0, during which only EBNA1, regulated by Qp 
promoter, is expressed [13]. EBV-infected B cells in Latency 
I lose proliferative capacity, but become almost undetectable 
by the immune system [14].
Early eBL cells are thought to derive from EBV-infected 
B cells that acquire IgH/c-myc translocation [3], probably 
through aberrant action of activation-induced cytidine deam-
inase (AID) [15], upregulated by EBV in Latency III [16]. 
EBV-infected eBL cells, however, harbor EBV in Latency I, 
with cell proliferation driven by deregulated c-myc expres-
sion due to IgH/c-myc translocation [3]. Therefore, Latency 
III to Latency I switch seems one of the key steps in eBL 
development, as it allows EBV-infected pre-eBL cells with 
an IgH/c-myc translocation to escape antiviral immunity. 
How and when this switch happens remains unclear.
The literature suggests that simultaneous expression 
of EBV and eBL growth programs is incompatible within 
the same cell [17–21]. Latency III depends on high NF-κB 
activity, while eBL cells usually show high c-myc activity 
and lack NF-κB signaling [17–21]. Furthermore, the EBV 
Latency III program is dominant over the c-myc growth pro-
gram [22–25], as the presence of IgH/c-myc translocation 
alone is not enough to turn an EBV-infected B cell into an 
eBL cell [22, 23], and overexpression of c-myc in Latency 
III B cells does not induce a switch to Latency I [24, 25]. 
Therefore, external factors are thought to induce the Latency 
III-to-Latency I switch in pre-eBL cells, but their specific 
nature remains unknown.
There is accumulating evidence that CD4 + T cells impact 
on eBL pathogenesis. Several studies have suggested that 
CD4 + T cells act as cytotoxic killer cells against EBV-
infected cells [26–29]. Other studies suggest that CD4 + T 
cells might support pre-eBL cells, like T follicular helper 
(Tfh) cell support healthy B cells, and, therefore, may inad-
vertently promote eBL development [30–33]. Particularly, 
in vitro co-culture studies have shown that at lower effec-
tor/target (E/T) ratios CD4 + T cells suppress B cell prolif-
eration [32] by inducing Latency III to Latency I switch, 
characterized by loss of EBNA2 [32, 33] and LMP1 [33] 
expression. Lack of suitable in vitro and in vivo models, 
however, considerably obstacle mechanistic studies of early 
eBL pathogenesis and immune system contribution to eBL 
development.
Here, we investigated the potential pathogenic role of 
CD4 + T cells in eBL based on the hypothesis of a dichoto-
mous impact of CD4 + T cells on eBL development. We 
hypothesize that CD4 + T cells interact with EBV-infected 
pre-eBL cells, similarly to Tfh cell interaction with a healthy 
B cell, leading to the suppression of the EBV Latency III 
program and reduction in EBV-infected cell outgrowth. 
While the switching to the BL Latency I suppresses the 
growth of EBV-infected B cells, it protects them from 
immune recognition. Moreover, we suggest that the Latency 
switch allows the rare IgH/c-myc-translocated cells to pro-
liferate by means of deregulated c-myc activity, resulting 
in subsequent neoplasia. Thus, we aimed at engineering 
a novel model of pre-eBL cells harboring an IgH/c-myc 
translocation to be used in co-cultures with CD4 + T cells 
in vitro. Using this model, we gathered important insights 
into CD4 + T cells interaction with pre-eBL cells and into 
their potential role in early events of eBL development.
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Material and methods
All kits/reagents were used according to manufacturer’s 
instructions unless otherwise stated. Details on antibodies 
and oligos are given in Tables 1, 2 and 3.
Patient material
The study was conducted according to the Helsinki Decla-
ration 1964 and approved by the regional ethics commit-
tees (Kantonale Ethikkommission Zürich, KEK-ZH Nr. 
StV 40/05, and University of the Witwatersrand, Johannes-
burg, South Africa, Nr. M180294). Human palatine tonsils 
were obtained from children undergoing routine tonsil-
lectomy at the University Children’s Hospital Zurich after 
informed parental consent. Thirteen archived cases of BL 
were retrieved from the Division of Anatomical Pathology, 
National Health Laboratory Service, Chris Hani Baragwa-
nath Academic Hospital, School of Pathology, University 
of the Witwatersrand, Johannesburg, South Africa. Tissue 
samples were fixed in 10% neutral buffered formalin. Ten 
recuts per patient were performed from paraffin tissue blocks 
and shipped to Zurich for immunohistochemistry (IHC). For 
additional patient information, see Supplementary Table 1.
Cell culture
Cells were cultured in cRPMI medium, prepared as 
described in [40]. For co-culture experiments, cRPMI media 
was supplemented with 20U/ml of human recombinant IL-2 
(Roche), referred as co-culture media.
Isolation of tonsillar mononuclear cells from tonsils
Tonsillar mononuclear cells (TMCs) were isolated from 
fresh tonsils as described [34].
Preparation of EBV virus stock and generation 
of lymphoblastoid cell lines
Concentrated EBV virus stock was prepared using B95-8/
ZHT cell line (kind gift from Micah Luftig) as described 
[35] and used for generation of lymphoblastoid cell lines 
(LCLs) from TMCs [34].
Isolation and expansion of CD4 + T cells
CD4 + T cells were isolated from TMCs using the CD4 
MicroBeads and the autoMACS Pro Separator (Milte-
nyi Biotec). CD4 + T cells were polyclonally expanded 
for 7–10d using CD3/CD28 beads (Dynabeads® Human 
T-Activator CD3/CD28, Gibco by Thermo Fisher Scientific). 
Prior to co-culture, CD4 + T cells were rested by withdrawal 
of IL-2 and CD3/CD28 beads for 24–48 h.
Co‑culture setup
Co-cultures between autologous LCLs and CD4 + T cells 
were set up in 6-well flat-bottom plates (Sarstedt) in 3 ml 
of co-culture media/well at 1.5mio/well total cell density. 
Anti-CD3/CD28 beads were used to stimulate T cells in co-
culture, unless stated “rested.” For 4:1 T cell/LCL cell ratio, 
1.2mio/well CD4 + T cells and 0.3mio/well LCL were ini-
tially plated. For 1:1 T cell/LCL ratio, 0.75mio/well of both 
CD4 + T cells and LCL were plated. For control conditions, 
CD4 + T cells and LCL were cultured alone at correspond-
ing cell densities. Cells were co-cultured for up to 9d, split 
every second day.
Post‑co‑culture separation of LCLs and CD4 + T cells
LCLs and CD4 + T cells from co-culture were separated 
using CD19 MicroBeads and autoMACS Pro Separator 
(both Miltenyi Biotec). Purity post-separation was deter-
mined using flow cytometry. Cells were then lysed for pro-
tein and RNA isolation.
Flow cytometry
For all stainings, cells were treated with Zombie viability 
dye and Fc receptor blocker and stained with anti-CD19 and 
anti-CD4 gating antibodies (Table 1). For surface marker 
stainings, cells were then stained with a corresponding 
panel of target-specific or isotype antibodies, washed and 
immediately acquired by flow cytometer. For apoptosis 
assay, after the surface staining cells were washed twice in 
Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, 
5 nM  CaCl2), they were stained with anti-human Annexin 
V antibody for 15 min on ice and then immediately acquired 
by flow cytometer. EdU incorporation assay was performed 
using Click-iT™ Plus EdU Alexa Fluor 647 Flow Cytometry 
Assay Kit (Invitrogen). For cell cycle analysis, FxCycle™ 
dye (Thermo Scientific) was added 30 min prior to acquisi-
tion by flow cytometer. Cytokine/transcription factor stain-
ing was performed using Foxp3/Transcription Factor Stain-
ing Buffer Kit (eBioscience by Thermo Scientific). Briefly, 
cytokine production in co-culture was induced by adding 
1 μg/ml PMA (Abcam) and 1 μg/ml Ionomycin (Abcam) 
for 4 h before harvesting. Brefeldin A at 5 μg/ml (Abcam) 
was added for 3 h prior to harvesting to induce cytokine 
accumulation in the cell. After the surface and viability 
stainings, cells were fixed, permeabilized and then stained 
with a corresponding panel of target-specific or isotype 
intracellular antibodies (see Table 1). BD LSRFortessa™ 
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Clone Cat Number Dilution Diluted in
Flow cytometry (FC) Human TruStain 
FcX
BioLegend 1.25 N/A 422,302
Zombie Red Viabil-
ity dye
BioLegend 0.1 N/A 423,109
Zombie NIR
Viability dye
BioLegend 0.1 N/A 423,105
Annexin V—APC BioLegend 1.25 N/A 640,919
FxCycle Violet Thermo Scientific 1 N/A R37166
CD19—APC/Cy7 BioLegend 2.5 HIB19 302,218
CD19—AlexaFluor 
700
BioLegend 1.25 HIB19 302,226
CD19—APC/Cy7 BioLegend 5 HIB19 302,218
CD4—BV711 Thermo Scientific 2.5 OKT4 67–0049-42
CD4—PerCp/Cy5.5 BioLegend 1.25 RPA-T4 300,529
CD40—PE/Cy7 BioLegend 2.5 5C3 334,321
CD40L—BV421 BioLegend 5 24–31 310,823
CD28—BV711 BioLegend 5 CD28.2 302,947
CD80—BV421 BioLegend 2.5 2D10 305,221
CD86—BV711 BioLegend 1.25 IT2.2 305,439
OX40—APC BioLegend 5 11C3.1 326,307
OX40L—PE BioLegend 2.5 ACT35 350,007
ICOS-L—APC BioLegend 5 11C3.1 326,307
ICOS—PE/Cy7 BioLegend 5 2D3 309,407
FASL—PE BioLegend 2.5 C398.4A 313,519
FAS—PE/Dazzle 
594
BioLegend 5 NOK-1 306,406
HLADR—PerCp/
Cy5.5
BioLegend 1.25 DX2 305,633
HLA A,B,C—
BV510
BioLegend 5 L243 307,629
IFNg—APC/Cy7 BioLegend 5 W6/32 311,435
T-bet—BV711 BioLegend 2.5 B27 506,523
IL13—BV421 BioLegend 2.5 4B10 644,819
GATA3—Alexa 488 BioLegend 2.5 JES10-5A2 501,915
IL21—Alexa 647 BioLegend 2.5 16E10A23 653,807
bcl6—PE BioLegend 2.5 3A3-N2 513,005
CD54—PerCp/
eFluor 710
Thermo Scientific 5 HA58 46–0549-41
CD10—PE/Cy5 BioLegend 20 HI10a 555,376
CD23—BV421 BioLegend 5 EBVCS-5 338,521
CD39—BV510 BioLegend 5 A1 328,219
FC CD38—APC Thermo Scientific 5 HIT2 17–0389-41
CD58—PE/Cy7 BioLegend 5 TS2/9 330,915
Cancer Immunology, Immunotherapy 
1 3
(BD Biosciences) with FACSDiva™ software was used for 
data acquisition; FlowJo 10.6 software was used for post-
acquisition analysis.
Western blotting
For total protein extraction, cells were lysed in RIPA buffer 
(Sigma-Aldrich) with protease inhibitor cocktail (cOmplete 
Tablet mini, Roche Diagnostics) and sonicated using an 
EpiShear™ Probe Sonicator (Active Motif) at 40% ampli-
tude for 2  s. Protein concentration was measured using 
Pierce™ 660 nm Protein Assay Kit (Pierce by Thermo Sci-
entific). Proteins were separated on 4–12% NuPage Gels 
(Invitrogen by Thermo Scientific) and transferred to either 
nitrocellulose membranes (GE Healthcare Life Science) 
or PVDF membranes (Thermo Scientific). Nitrocellulose 
membranes were blocked with 5% nonfat dry milk and 
used for detection with HRP secondary antibodies. PVDF 
membranes, blocked with 1X Blocker ™ FL Fluorescent 
Blocking Buffer (Thermo Scientific) and fluorescent sec-
ondary antibodies for β-actin were used. HRP signal was 
detected using Amersham ECL™ Western Blotting Reagent 
(GE Healthcare Life Science). ChemiDoc Imaging System 
(Bio-Rad Laboratories) was used to acquire both HRP and 
fluorescent signal. Band intensity (volume) for proteins of 
interest was quantified using ImageLab 6 (Bio-Rad Labora-
tories) software and normalized to loading control (β-actin).
qRT‑PCR
RNA was isolated using either Quick-RNA MiniPrep Kit 
(Zymo Research) with additional DNase treatment (ezD-
Nase™, Thermo Scientific). RNA concentration was meas-
ured using NanoDrop (Thermo Scientific). cDNA was gen-
erated using High-Capacity cDNA Reverse Transcription 
Kit (Thermo Scientific). Gene expression was measured 
using either pre-designed TaqMan assays (IDT) or in-house 
designed primer–probe mixes (synthesized by Microsynth). 
Primer/probe sequences for Cp and Qp promoter usage assay 
were obtained from [36]. qRT-PCR was performed on a 
CFX384 Touch Real-Time PCR Detection System (Bio-Rad 
Laboratories AG) or 7900HT Fast Real-Time PCR System 
(Thermo Fisher Scientific). LCL gene expression was nor-
malized to the geometric mean of 2 endogenous controls 






Clone Cat Number Dilution Diluted in
Western Blot Mouse anti-human 
EBNA2
Abcam PE2 ab90543 1:1000 5% Milk/TBS-T
Mouse anti-human 
LMP1
Abcam CS 1–4 ab78113 1:1000 5% Milk/TBS-T
Rabbit anti-human 
c-myc
Abcam Y69 ab32072 1:2500 5% Milk/TBS-T
Rabbit anti-human 
β-actin
Abcam polyclonal 4967S 1:1000 5% Milk/TBS-T
Rabbit anti-human 
β-actin






Cell Signaling polyclonal 7076S 1:1000 5% Milk/TBS-T
Goat anti-rabbit HRP 
(secondary)




Thermo Scientific polyclonal A32731 1:10,000 
(Fluores-
cent)
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(TBP and YWHAZ) using dCt method. Endogenous controls 
were selected based on stability pre-validation using qbase 
3.2 software.
Fluorescent in situ hybridization (FISH)
In total, 100 000 LCLs were attached to microscopy slides 
using Cytospin funnels (500 rpm for 5 min at RT), fixed with 
70% ethanol (15 min at 4C) and stored at -20C until the day 
of the analysis.
2.5 μl of IgH/c-myc translocation dual fusion probe 
(LPH-041, Cytocell) was added per slide, and slides were 
incubated in thermal cycler (2 min at 75C then at 37C 
overnight). Next day, slides were washed with 0.4xSSC 
(2 min at 72C) and 2xSSC + 0.05% Tween-20 (1 min at 
RT). Samples were then counterstained with DAPI, and 
images were acquired using Metafer Slide Scanning Plat-
form (MetaSystems).
Table 2  List of PCR, gDNA PCR and qRT-PCR primer/probes
Gene/Sequence name Direction Sequence or assay ID Supplier
Cloning (PCR) c-myc PCR-1F Forward 5'-CCG CCA TCT TTA GCA ACT TTC-3' Microsynth (custom)
c-myc PCR-1R Reverse 5'-CAC AGC AGA AGG TGA TGG GTA-3'
IgH PCR-1F Forward 5'-CGA GAT GCC TGA ACA AAC CA-3'
IgH PCR-1R Reverse 5'-CTT GCT TTG GCC TCA ATT CC-3'
GFP PCR-1F Forward 5'-CCG CGT TAC ATA ACT TAC GG-3'
GFP PCR-1R Reverse 5'-AAC TTG TTT ATT GCA GCT TAT AAT GGT-3'
gDNA PCR gDNA nPCR-1F Forward 5'-ATC CGC CAT CTT TAG CAA CTT T-3'
gDNA nPCR-1R Reverse 5'-CTG AGC ATT GCA GGT TGG TC-3'
gDNA nPCR-2F Forward 5'-AAT TCA TCT GCT TCC AGC TT-3'
gDNA nPCR-2R Reverse 5'-TAT GGA GAA CCG GTA ATG GCA-3'
gDNA nPCR-3F Forward 5'-TAC CCT ATG AGG TCA AGC TG-3'
gDNA nPCR-3R Reverse 5'-ACA AAC CAG GGG TCT TAG TG-3'
qRT-PCR gDNA nPCR-4F Forward 5'-TAT GAT GGT CAA AAC GCA GTC-3'
gDNA nPCR-4R Reverse 5'-CCC CCA CGT CTT AGA AAC TC-3'
EBNA2 Forward 5'-GGG ATG CCT GGA CAC AAG AG-3'
Reverse 5'-CAT GCC CGA CGT CAT ATC CT-3'
Probe FAM-5'-CAT CAC CTC TTG ATA GGG ATC CGC -3'-BHQ1
LMP1 Forward 5’-TGG AGC CCT TTG TAT ACT CCT-3’
Reverse 5’TGC CTG TCC GTG CAA ATT C-3’
Probe FAM-5’-TGA TCA CCC TCC TGC TCA TCG CTC T-3’-BHQ1
EBNA1 Cp Forward 5'-TGC CTG AAC CTG TGG TTG G-3'
Reverse 5'-CAT GAT TCA CAC TTA AAG GAG ACG G-3'
Probe FAM-5'-TCC TCT GGA GCC TGA CCT GTG ATC G-3'-BHQ1
EBNA1 Qp Forward 5'-GTG CGC TAC CGG ATG GC-3'
Reverse 5'-CAT GAT TCA CAC TTA AAG GAG ACG G-3'
Probe FAM-5'-TCC TCT GGA GCC TGA CCT GTG ATC G-3'-BHQ1
bcl6 Hs.PT.56a.19673829.g (Dye: FAM) IDT®
c-myc Hs.PT.58.26770695 (Dye: FAM) IDT®
IFNγ Hs.PT.58.3781960 (Dye: FAM) IDT®
IL-13 Hs00174379_m1 (Dye: FAM) Thermo Fisher
IL-21 Hs.PT.58.22750196 (Dye: FAM) IDT®
TBX21 Hs.PT.58.3936407 (Dye: FAM) IDT®
GATA3 Hs.PT.58.4308511 (Dye: FAM) IDT®
bcl6 Hs.PT.56a.19673829.g (Dye: FAM) IDT®
POLR2A Hs.PT.39a.19639531 (Dye: FAM) IDT®
UBC Hs.PT.39a.22214853 (Dye: Cy5) IDT®
TBP Hs.PT.39a.22214825 (Dye: FAM) IDT®
YWHAZ Hs.PT.39a.22214858 (Dye: FAM) IDT®
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Table 3  crRNA, ssDNA, PCR primer sequences
Sequence name Sequence (5′-3′)
crRNA IgH1 5′ AltR1-CCG UAA AAA CCU ACU UGA CCG UUU UAG AGC UAU GCU -AltR2-3′
crRNA IgH7 5′ AltR1-CCG AAG GAU CGC UUU AAC CGG UUU UAG AGC UAU GCU -AltR2-3′
crRNA IgH10 5′ AltR1-CCU CGG UUA AAG CGA UCC UUG UUU UAG AGC UAUGC-AltR2-3′
crRNA c-myc4 5′ AltR1-GGA CGG CAG CCA CCG UUU CUG UUU UAG AGC UAU GCU -AltR2-3′
crRNA c-myc5 5′ AltR1-GCC GUC CUG ACA GGG GCU UAG UUU UAG AGC UAU GCU -AltR2-3′
crRNA c-myc6 5′ AltR1-GCC CCG GUC UUG AUG AGA GCG UUU UAG AGC UAU GCU -AltR2-3′
GFP PCR-1F 5′-CCG CGT TAC ATA ACT TAC GG-3′
GFP PCR-1R 5′-AAC TTG TTT ATT GCA GCT TAT AAT GGT-3′
STR1-F 5′ GGC TTC TGA GGC GGA AAG′
STR1-R 5′ CTT TTT ACG GTT CCT GGC CTT′
IgH gene block 5′cggaaagaaccagcGGC GCG AGT GCC AGA TTC CTG GGA AAT CAG CCT ACA AGG CTC CTG CGG GAA GGA ACC TCC 
ACT GCC AGA AGT CCT TAG GGC ATC TAA GTG ATC AGA CAC CGT CAG GGA TTC TTT GCC CCG TAA AAA CCT 
ACT TGA CCA GGG ACA CGT GCC AGG TAA ATT TCC TTC ACA TTT ACT TCA ACC TTA TTG CAT ACT CAT TTT AGT 
ATT AAA ACC TTT AAT AAA ATG CTC CTA TTC CTT CAC ACT TTT TTT CTA TGA GAT CTC AAA TAC CCC TTC TTG 
CTA TTA AAA AAA ATC ACT TAT TAT TCA CCA GCC CAA TAT TTT AAA AGT AAA AAT AAT AAG CCA AGG CCA 
GGA GCG ATG ACT CGC ACT TGT ATT CCC AGC AGT TTC AGA GGC AAA GGC CGA AGG ATC GCT TTA ACC GCG 
TTA CAT AAC TTA CGG -3′
c-myc gene block 5′TAA GCT GCA ATA AAC AAG TTC TCA TCA AGA CCG GGG CTA CGC GTC CCT CCT GGC TGG ATT CAC CCA CTC 
CGA CAG TTC TCT TTC CAG CCA ATA AAG AAT TTA AGA TGC AGG TTG ACA CAC AGC GCA CCT CAT AAT TCT 
AAA GAA AAT ATT TCA CGA TTC GCT GCT GTG CAG CGA TCT TGC AGT CCT ACA GAC ACC GCT CCT GAG ACA 
CAT TCC TCA GCC ATC ACT AAG ACC CCT GGT TTG TTC AGG CAT CTC GTC CAA ATG TGG CTC CCC AAG CCC 
CCA GGC TCA GTT ACT CCA TCA GAC GCA CCC AAC CTG AGT CCC ATT TTC CAA AGG CAT CGG AAA ATC CAC 
AGA GGC TCC CAG ATC CTC AAG GCA CCC CAG TGC CCA TCC CCT CCT GGC CAG TCC GCC CAG GTC CCC TCG 
GAA CAT CTAGCcaaaaggccaggaac-3′
GFP + CMV ssDNA 5′GGC TTC tgaggcggaaagaaccagcGGC GCG AGT GCC AGA TTC CTG GGA AAT CAG CCT ACA AGG CTC CTG CGG GAA 
GGA ACC TCC ACT GCC AGA AGT CCT TAG GGC ATC TAA GTG ATC AGA CAC CGT CAG GGA TTC TTT GCC CCG 
TAA AAA CCT ACT TGA CCA GGG ACA CGT GCC AGG TAA ATT TCC TTC ACA TTT ACT TCA ACC TTA TTG CAT ACT 
CAT TTT AGT ATT AAA ACC TTT AAT AAA ATG CTC CTA TTC CTT CAC ACT TTT TTT CTA TGA GAT CTC AAA TAC 
CCC TTC TTG CTA TTA AAA AAA ATC ACT TAT TAT TCA CCA GCC CAA TAT TTT AAA AGT AAA AAT AAT AAG CCA 
AGG CCA GGA GCG ATG ACT CGC ACT TGT ATT CCC AGC AGT TTC AGA GGC AAA GGC CGA AGG ATC GCT TTA 
ACC GCG TTA CAT AAC TTA CGG TAA ATG GCC CGC CTG GCT GAC CGC CCA ACG ACC CCC GCC CAT TGA CGT 
CAA TAA TGA CGT ATG TTC CCA TAG TAA CGC CAA TAG GGA CTT TCC ATT GAC GTC AAT GGG TGG AGT ATT 
TAC GGT AAA CTG CCC ACT GGC AGT ACA TCA AGT GTA TCA TAT GCC AAG TCC GCC CCC TAT TGA CGT CAA 
TGA CGG TAA ATG GCC CGC CTG GCA TTA TGC CCA GTA CAT GAC CTT ACG GGA CTT TCC TAC TTG GCA GTA 
CAT CTA CGT ATT AGT CAT CGC TAT TAC CAT GGT GAT GCG GTT TTG GCA GTA CAC CAA TGG GCG TGG ATA GCG 
GTT TGA CTC ACG GGG ATT TCC AAG TCT CCA CCC CAT TGA CGT CAA TGG GAG TTT GTT TTG GCA CCA AAA 
TCA ACG GGA CTT TCC AAA ATG TCG TAA TAA CCC CGC CCC GTT GAC GCA AAT GGG CGG TAG GCG TGT ACG 
GTG GGA GGT CTA TAT AAG CAG AGG TCG TTT AGT GAA CCG TCA GAT CAC TAG TAG CTT TAT TGC GGT AGT TTA 
TCA CAG TTA AAT TGC TAA CGC AGT CAG TGC TCG ACT GAT CAC AGG TAA GTA TCA AGG TTA CAA GAC AGG 
TTT AAG GAG GCC AAT AGA AAC TGG GCT TGT CGA GAC AGA GAA GAT TCT TGC GTT TCT GAT AGG CAC CTA 
TTG GTC TTA CTG ACA TCC ACT TTG CCT TTC TCT CCA CAG GGG TAC CGA AGC CGC TAG CGC TAC CGG TCG 
CCA CCA TGC CCG CCA TGA AGA TCG AGT GCC GCA TCA CCG GCA CCC TGA ACG GCG TGG AGT TCG AGC TGG 
TGG GCG GCG GAG AGG GCA CCC CCG AGC AGG GCC GCA TGA CCA ACA AGA TGA AGA GCA CCA AAG GCG 
CCC TGA CCT TCA GCC CCT ACC TGC TGA GCC ACG TGA TGG GCT ACG GCT TCT ACC ACT TCG GCA CCT ACC 
CCA GCG GCT ACG AGA ACC CCT TCC TGC ACG CCA TCA ACA ACG GCG GCT ACA CCA ACA CCC GCA TCG AGA 
AGT ACG AGG ACG GCG GCG TGC TGC ACG TGA GCT TCA GCT ACC GCT ACG AGG CCG GCC GCG TGA TCG GCG 
ACT TCA AGG TGG TGG GCA CCG GCT TCC CCG AGG ACA GCG TGA TCT TCA CCG ACA AGA TCA TCC GCA GCA 
ACG CCA CCG TGG AGC ACC TGC ACC CCA TGG GCG ATA ACG TGC TGG TGG GCA GCT TCG CCC GCA CCT TCA 
GCC TGC GCG ACG GCG GCT ACT ACA GCT TCG TGG TGG ACA GCC ACA TGC ACT TCA AGA GCG CCA TCC ACC 
CCA GCA TCC TGC AGA ACG GGG GCC CCA TGT TCG CCT TCC GCC GCG TGG AGG AGC TGC ACA GCA ACA CCG 
AGC TGG GCA TCG TGG AGT ACC AGC ACG CCT TCA AGA CCC CCA TCG CCT TCG CCA GAT CTC GAG CTC GAT 
GAG TTT GGA CAA ACC ACA ACT AGA ATG CAG TGA AAA AAA TGC TTT ATT TGT GAA ATT TGT GAT GCT ATT 
GCT TTA TTT GTA ACC ATT ATA AGC TGC AAT AAA CAA GTT CTC ATC AAG ACC GGG GCT ACG CGT CCC TCC 
TGG CTG GAT TCA CCC ACT CCG ACA GTT CTC TTT CCA GCC AAT AAA GAA TTT AAG ATG CAG GTT GAC ACA 
CAG CGC ACC TCA TAA TTC TAA AGA AAA TAT TTC ACG ATT CGC TGC TGT GCA GCG ATC TTG CAG TCC TAC 
AGA CAC CGC TCC TGA GAC ACA TTC CTC AGC CAT CAC TAA GAC CCC TGG TTT GTT CAG GCA TCT CGT CCA 
AAT GTG GCT CCC CAA GCC CCC AGG CTC AGT TAC TCC ATC AGA CGC ACC CAA CCT GAG TCC CAT TTT CCA 
AAG GCA TCG GAA AAT CCA CAG AGG CTC CCA GAT CCT CAA GGC ACC CCA GTG CCC ATC CCC TCC TGG CCA 
GTC CGC CCA GGT CCC CTC GGA ACA TCT AGC caaaaggccaggaaccgtaaaAAG-3′
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Immunohistochemistry (IHC)
Biopsy specimens were fixed in 10% buffered formalin, 
embedded in paraffin and stained with hematoxylin and 
eosin (H&E). The immunohistochemical stains were 
conducted using a Leica BOND-MAX stainer (Leica 
Microsystems). Antigen retrieval included the application 
of ER2 solution (Leica Microsystems). Sections of human 
tonsils were used as positive controls.
Evaluation of the IHC slides and data analysis
All slides were evaluated by one of the coauthors (W.K.) 
blinded to clinical data. Total cell number of the biopsy 
was estimated by counting cells based on hematoxylin and 
eosin staining, and the number of marker-positive cells 
was estimated by counting marker-positive cells. The 
results were given in percentage of the whole number of 
cells compared to the entire infiltrate and scored as (0) 
negative, (1) < 1%, (2) 1–5%, (3) 6–10%, (4) 11–20%, (5) 
21–30%. Individual scores can be found in Supplemen-
tary Fig. 2. Representative images were taken with Axio 
Observer Z1 (Zeiss) and Digital Camera ORCA Flash 4.0 
(Hamamatsu) using TL Brightfield channel. Images were 
not edited except of adjustment of Black/White intensity.
Generation of IgH/c‑myc + LCLs using CRISPR/CAS9 
approach
crRNAs for IgH and c-myc regions were designed using 
the online tool (www. crispr. mit. edu). CAS9 ribonuclear 
protein complexes (RNPs) were formed in vitro from spe-
cific crRNAs (synthesized by IDT), standardized tracr-
RNA (Alt-R CRISPR-CAS9 tracrRNA, IDT) and CAS9 
protein (Alt-R S.p. CAS9 Nuclease V2, IDT). Then, 200 
000 LCLs were electroporated with CAS9 RNPs (1.5 μM 
each), ssDNA template (1 μg/transfection) and 1.8 μM 
of transfection enhancer (IDT) in 10 μl tips using Neon 
Transfection System (Thermo Scientific) at 1400  V, 
10 ms, 3 pulses. Electroporated cells were outgrown for 
2 weeks, and GFP + cells were flow-sorted using FAC-
SAria Fusion cell sorter (BD Biosciences). Cells were 
grown for 2 additional weeks, and purity was regularly 
checked by monitoring percentage of GFP + cells by flow 
cytometer. Additional sorts were performed if percentage 
of GFP + cells dropped significantly.
Generation of ssDNA for GFP knock‑in
ssDNA insert was designed to consist of GFP driven by 
CMV promoter, flanked by two 400 bp regions homologous 
to IgH and c-myc regions near to breakpoint. IgH and c-myc 
homology regions were added in order to facilitate specific 
integration of GFP + CMV insert into reciprocal translocation 
breakpoint. ssDNA insert was generated using Guide-it Long 
ssDNA production system (Takara Bio). Briefly, we assembled 
400 bp homology regions (ordered as GeneBlocks from IDT), 
GFP + CMV insert (amplified by PCR from pmax-GFP plas-
mid (Amaxa, Lonza) using GFP-PCR1 primers) and backbone 
from pcDNA3.1 plasmid (Invitrogen, Thermo Scientific) using 
In-Fusion HD Cloning Plus kit (Takara Bio). Then, we gener-
ated PCR product using Phusion High-Fidelity DNA polymer-
ase (Thermo Scientific) and STR1 primers and digested sense 
strand of PCR using Strandase enzyme (from ssDNA produc-
tion system). ssDNA was then isolated using NucleoSpin Gel 
and PCR Clean-Up Kit (Takara Bio).
gDNA PCR
Genomic DNA (gDNA) was isolated using DNAeasy Blood 
and Tissue Kit (Qiagen). DNA concentration was determined 
by NanoDrop (Thermo Scientific). PCR was performed using 
Phusion High-Fidelity DNA polymerase (Thermo Scientific). 
The second round of nested PCR was performed by diluting 
product of first-round PCR 1:100 in  ddH20.
Statistical analysis and graph design
Statistical analysis was performed using GraphPad Prism 
8.4.3 (GraphPad Software). Graphs and drawings were cre-
ated using GraphPad Prism 8.4.3 (GraphPad Software) and 
PowerPoint 2019 (Microsoft Corporation).
Results
CD4 + T cells are present in primary eBL tissue
Given that the presence of CD4 + T cells in primary eBL 
tumors has not been reported before, we assessed the 
Table 3  (continued)
Sequence name Sequence (5′-3′)
pmax-GFP plasmid http:// www. addge ne. org/ vector- datab ase/ 3525/
pcDNA3.1 https:// www. addge ne. org/ vector- datab ase/ 2093/
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presence and frequency of T cells in eBL tissue from 13 
patients using IHC. CD3 + , CD4 + and CD8 + cells were 
present in all eBL samples, mostly at similar frequencies 
(1–5% of total cells), independent of tumors’ anatomic ori-
gin (Fig. 1b). However, CD3 + and CD8 + cells appear to be 
more numerous as compared to CD4 + cells (Fig. 1a and b).
The above results unprecedentedly show that CD4 + T 
cells are present in primary eBL tumor tissue and thus likely 
are present at the site of eBL development, suggesting that 
they may contribute to eBL pathogenesis.
CD4 + T cells suppress pre‑eBL cell outgrowth 
in vitro by reducing their viability
Having demonstrated the presence of CD4 + T cells in pri-
mary eBL tissue, we addressed their possible impact on pre-
eBL cells. To this end, we set up co-cultures of polyclonal 
aCD3/CD28 beads-activated CD4 + T cells with autolo-
gous LCLs and assessed LCL proliferation, viability and 
cell cycle phases using flow cytometry. We chose LCLs to 
model pre-eBL EBV-infected B cell for two reasons: First, 
EBV in LCLs is in Latency III, as it is in pre-eBL cells 
prior to acquiring the IgH/c-myc translocation; and second, 
LCLs derived from tonsils allow setting up co-cultures 
with autologous CD4 + T cells. We used polyclonally acti-
vated CD4 + T cells rather than EBV-specific CD4 + T cell 
lines, since this allows working with a heterogeneous pool 
of CD4 + T cells, as expected to be found in lymph nodes/
tonsils during eBL initiation. Moreover, polyclonal stimula-
tion may mimic chronic stimulation of CD4 + T cells as in 
chronic malaria with which eBL is tightly associated [37].
In contrast to previous reports [32], we could not detect 
any effect of CD4 + T cells on LCL proliferation (Fig. 2a, 
d), nor on the relative percentage of LCLs in different T cell 
cycle phases (Fig. 2b, e) at any of the time points assessed, 
strongly suggesting that CD4 + T cells have no effect on LCL 
proliferation in our co-culture model. However, we observed 
a markedly reduced viability of LCLs proportionally to the 
number of CD4 + T cells used, while the proportion of apop-
totic cells was longitudinally not affected (Fig. 2c, f).
These results suggest that CD4 + T cells suppress pre-
eBL cell outgrowth by reducing their viability, rather than 
by affecting their proliferation.
CD4 + T cells induce switch toward eBL phenotype 
in pre‑eBL cells
As CD4 + T cells reduced the viability of pre-eBL cells in 
our in vitro system, we hypothesized that CD4 + T cells 
may promote eBL development indirectly by suppressing 
the immunogenic EBV Latency III program, allowing pre-
eBL cells to escape immune control. To test this, we ana-
lyzed changes in expression of several crucial EBV and BL 
markers in LCLs after co-culture with autologous CD4 + T 
cells. CD4 + T cells suppressed EBNA2 expression on both 
mRNA (Fig. 3a) and protein (Fig. 3b, Supplementary Fig. 1) 
levels and reduced Cp promoter usage in LCLs (Fig. 3c). 
Furthermore, activated CD4 + T cells induced stronger 
suppression of EBNA2 protein than non-activated T cells 
(Fig. 3b). Notably, there was no effect of CD4 + T cells on 
LMP1 mRNA (Fig. 3a) or protein (Fig. 3d, Supplementary 
Fig. 1) levels nor on Qp promoter usage (Fig. 3c). This sug-
gests that while CD4 + T cells initiate switch from the domi-
nant Latency III toward Latency I by decreasing EBNA2 
expression, the switch is not complete as in eBL, where 
LMP1 expression is absent. Furthermore, while we did not 
observe any effect of CD4 + T cells on c-myc expression lev-
els (Supplementary Figs. 1, 10), CD4 + T cells upregulated 
bcl6 mRNA expression in LCLs (Supplementary Fig. 10). 
As bcl6 is one of the key markers of eBL, this further sup-
ports the notion that CD4 + T cells initiate phenotypic 
changes in LCLs leading to eBL.
Overall, these data suggest that while CD4 + T cells do 
not directly promote pre-eBL cell outgrowth, by reducing 
EBNA2 expression they initiate a switch of EBV Latency 
toward an eBL-like phenotype. This, in turn, may promote 
the switch of cells with eBL-associated mutations and trans-
locations to the EBV Latency I program through suppression 
of dominant EBV phenotype Latency III.
CD4 + T cells can interact with pre‑BL cells 
via both contact‑dependent and soluble mediators
Next, we wanted to gain information about the possible 
mechanisms underlying the changes in viability and gene 
expression observed in LCLs upon co-incubation with 
autologous CD4 + T cells. To this end, we first assessed 
the expression of several co-stimulatory molecules pairs, 
known to be involved in antigen-presenting cell (APC)–T 
cell interaction [38], using flow cytometry. LCLs in co-cul-
ture with CD4 + T cells expressed high levels of CD80/86 
and CD40 as well as lower but detectable levels of ICOS-L 
and OX40L (Fig. 4a, 4b, Supplementary Figure S2a), while 
CD4 + T cells expressed OX40, CD40L and ICOS as well 
as low levels of CD28 (Fig. 4c, 4d, Supplementary Figure 
S2b). Thus, both the CD4 + T cells and the LCLs expressed 
their part of the co-stimulatory pairs of the four pathways 
we investigated, supporting the notion that CD4 + T cells 
can affect the phenotype of LCL through conventional T–B 
cell interaction pathways. Furthermore, we could observe a 
downregulation of CD40L on CD4 + T cells upon co-culture 
with LCLs (Fig. 4g), indicating an active CD40L–CD40 
interaction.
Secondly, we assessed the CD4 + T helper subset com-
position and CD4 + T cell-derived cytokines in co-culture 
using both flow cytometry and qRT-PCR. We observed 
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Fig. 1  CD4 + T cells are present 
in primary eBL tissue. Recuts 
from 13 eBL patient biopsy 
samples were stained for 
CD3, CD4 and CD8 mark-
ers. a Images of CD3, CD4 
and CD8 stainings from one 
representative eBL patient 
(BL13) at 5 × or 20 × resolution. 
At 5 × resolution measure bar 
is 200 μm, at 20 × resolution 
measure bar is 50 μm for all 
images. b Mean IHC evalua-
tion score for 13 patients used 
for the analysis. p values were 
calculated using paired one-way 
ANOVA with Sidak’s test for 
multiple comparisons. p > 0.05 
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a high proportion of Th1 cells (T-bet + , IFNγ +), but 
no Th2 cells (GATA3 + , IL-13 +) or Tfh cells (bcl6 + , 
IL-21 +) by flow cytometry (Fig. 4e, 4f, Supplementary 
Figure S2c). Furthermore, we detected IL-21 and IL-13 
on mRNA level (Fig. 4h), but no intracellular protein by 
flow cytometry (Fig. 4e, 4f). IFNγ, in contrast, was highly 
expressed at both mRNA and protein level.
Collectively, these data suggest that CD4 + T cells in 
co-culture are predominantly of Th1 phenotype and that 
Fig. 2  Effect of CD4 + T cells 
on LCL proliferation, cell 
cycle and viability. LCLs were 
cultured for 9 days either alone 
or in co-culture at various ratios 
with expanded autologous 
CD4 + T cells activated using 
anti-CD3/CD28 beads. At given 
times cells were harvested, 
stained and analyzed using flow 
cytometry. LCLs were pre-gated 
based on CD19 expression. 
Shown are mean ± SD of mean 
percentage of positive cells 
from 3 TMC donors a Mean 
percentage of EdU + LCLs 
was measured using Click-iT 
Flow Cytometry kit. p values 
were calculated using two-way 
ANOVA with Sidak’s test for 
multiple comparisons. p > 0.05 
not significant (n.s.) b Mean 
percentage of LCLs in different 
cell cycle stages was meas-
ured using EdU Click-iT Flow 
cytometry kit and FxCycle dye. 
c Mean percentage of dead, 
apoptotic and living LCLs was 
measured using Annexin V stain 
and Zombie Viability stain. 
d Histogram overlay used for 
gating on EdU + and EdU- cells 
from one representative donor. e 
Pseudocolor plot used for gating 
on cells in G1, G2 and S phases 
of cell cycle for cell cycle assay 
from one representative donor. f 
Pseudocolor plot used for gating 
on living, apoptotic and dead 
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IFNγ and CD40L are likely to be involved in CD4 + T-cell-
mediated changes in LCL phenotype.
Establishment and validation of a novel model 
of IgH/c‑myc translocation and knock‑in of a GFP tag 
in pre‑BL cells using CRISPR/CAS9
In order to mechanistically test whether suppression of the 
EBV Latency III by CD4 + T cells allows pre-eBL cells 
with eBL-associated genetic abnormalities to switch to the 
Latency I program, we modeled the main eBL-associated 
genetic abnormality, i.e., the IgH/c-myc translocation. For 
this, we generated LCLs from four healthy donors with and 
without IgH/c-myc translocation using CRISPR/CAS9 tech-
nology. To facilitate selection of rare IgH/c-myc + cells, we 
introduced a CMV-driven GFP tag into the reciprocal trans-
location breakpoint (Fig. 5a).
First, we designed and validated gRNAs capable of 
introducing dsDNA breakpoints into relevant c-myc and 
IgH regions, selecting the most efficient gRNAs using Sur-
veyor assay (Supplementary Fig. 3). Next, we tested whether 
the introduction of simultaneous dsDNA breaks in c-myc 
Fig. 3  Effect of CD4 + T cells 
on LCL EBV Latency stage and 
EBV gene expression. LCLs 
were cultured for 7 days either 
alone or in co-culture at various 
ratios with expanded autolo-
gous CD4 + T cells activated 
using anti-CD3/CD28 beads. 
At given time points, cells were 
harvested and LCLs were iso-
lated using CD19 + beads and 
autoMACS. Different symbols 
represent different conditions, 
while different colors represent 
different TMC donors. p values 
were calculated using two-way 
ANOVA with Sidak’s test for 
multiple comparisons. p > 0.05 
not significant (n.s.), p < 0.1*, 
p < 0.01**, p < 0.001***. WB 
images used for quantifica-
tion can be found in Supple-
mentary Fig. 1. a EBNA2 and 
LMP1 expression at 5:1 T cell/
LCL ratio was determined 
using qRT-PCR. Shown are 
mean ± SD of dCt values 
normalized to geometric means 
of TBP and YWHAZ. b Total 
EBNA2 protein expression was 
assessed using Western blotting. 
Western blot image was quanti-
fied and normalized to β-actin 
as loading control. Shown 
are mean ± SD of normalized 
volume of EBNA2 band. c Cp 
and Qp promoter usage at 5:1 T 
cell/LCL ratio was determined 
using qRT-PCR. Shown are 
mean ± SD of dCt values 
normalized to geometric means 
of TBP and YWHAZ. d Total 
LMP1 protein expression was 
assessed using Western blotting. 
Western blot image was quanti-
fied and normalized to β-actin 
as loading control. Shown 
are mean ± SD of normalized 
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Fig. 4  Expression of co-stimulatory molecules and T helper subset-
associated markers in in  vitro T cell–LCL co-culture system. LCLs 
were cultured either alone or in co-culture with 1:3 LCL/T cell ratio 
of expanded autologous CD4 + T cells activated using anti-CD3/
CD28 beads. CD4 + T cells were cultured alone either activated with 
beads or rested as a control. After 5  days of co-culture, cells were 
harvested, stained and analyzed using flow cytometer. LCLs were 
pre-gated based on CD19 expression. T cells were pre-gated based 
on CD4 expression. Isotype staining was used to determine posi-
tive cells. Shown are mean ± SD of either mean fluorescent intensity 
(MFI) or percentage of positive cells. Different symbols represent 
different conditions, while different colors represent different TMC 
donors. Histogram overlays for one representative donor can be found 
in Supplementary Fig.  2. a, b Mean fluorescent intensity (MFI) (a) 
and percentage of positive cells (b) for expression of surface co-stim-
ulatory molecules on LCLs. c, d Mean fluorescent intensity (MFI) (c) 
and percentage of positive cells (d) for expression of surface co-stim-
ulatory molecules on CD4 + T cells. e, f Mean fluorescent intensity 
(MFI) (e) and percentage of positive cells (f) for cytokine production 
and transcription factor expression in CD4 + T cells. g. Histogram 
overlay for CD40L expression for one representative donor. h After 
5 days of co-culture, CD4 + T cells were isolated by negative selec-
tion using CD19 + beads and autoMACS. Gene expression was deter-
mined using qRT-PCR. Shown are mean ± SD of dCT values normal-
ized to geometric means of POL2A, UBC and TBP 








Fig. 5  Generation and validation of IgH/c-myc + LCLs. a Over-
all experimental setup for generation of IgH/c-myc + LCLs. b-e 
LCL line was electroporated with IgH/c-myc targeting CAS9 RNPs 
and with ssDNA template containing the CMV-GFP insert. Cells 
were outgrown for 14  days, and then GFP + cells were sorted using 
FACS. GFP signal and presence of the translocations of interest were 
assessed using flow cytometry (b) and nested PCR (c). Highlighted 
PCR bands from nPCR assay were sequenced to confirm identity of 
the bands (d). Presence of IgH/c-myc translocation was confirmed by 
dual-probe FISH (e). Repeats performed on additional donors can be 
found in Supplementary Fig. 5
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and IgH regions resulted in IgH/c-myc translocation. We 
confirmed the presence of translocations by gDNA PCR 
(Supplementary Fig. 4). Then, we generated and validated 
a ssDNA insert, designed to integrate a CMV + GFP tag into 
the reciprocal translocation (Fig. 5a, Supplementary Fig. 5). 
Next, we generated and sorted IgH/c-myc + LCLs with GFP 
expressed from the insert in the reciprocal translocation 
breakpoint (Fig. 5b) and confirmed the presence of translo-
cation by gDNA PCR (Fig. 5c) by sequencing (Fig. 5d), as 
well as by FISH (Fig. 5e, Supplementary Fig. 6).
Finally, we tested if the presence of the translocation 
alone has any effect on the LCL phenotype and assessed 
differences in proliferation (Fig. 6a), viability (Fig. 6b) and 
cell cycle distribution (Fig. 6c) of IgH/c-myc + LCLs as 
compared to WT LCLs. We could not detect any significant 
differences between WT and IgH/c-myc + LCLs in RNA 
(Figure S8a, Fig. 6e) and protein (Fig. 6d, Supplementary 
Fig. 7) levels of any of the eBL/EBV growth program mark-
ers tested nor on Cp/Qp promoter usage (Fig. 6f). Further-
more, we did not observe any effect of translocation alone 
on expression of co-stimulatory molecules, involved in T 
cell/LCL interaction (Fig. 6g, Supplementary Figure S8b) 
or on expression of surface markers, commonly associated 
with EBV or eBL phenotype (Fig. 6h, Supplementary Figure 
S8c).
Overall, our observations are in line with the established 
premise that the translocation alone is not sufficient for eBL 
development.
IgH/c‑myc + pre‑eBL cells do not escape viability 
suppression by CD4 + T cells
Next, we used our translocation model to test whether IgH/c-
myc + LCLs survive the interaction with CD4 + T cells better 
than WT LCLs. Thus, we cultured parental WT and offspring 
IgH/c-myc + LCLs in the presence of CD4 + T cells and 
assessed changes in proliferation, viability and mRNA/pro-
tein levels of several crucial eBL and EBV markers. While 
CD4 + T cells outgrew both WT and IgH/c-myc + LCLs, 
they tended to outgrow IgH/c-myc + LCLs faster than WT 
LCLs at both 5:1 (Fig. 7a) and 1:1 E/T ratio (Supplementary 
Fig. 8). At a 5:1 ratio, CD4 + T cells suppressed the viability 
of WT and IgH/c-myc + LCLs to a similar extent, while at 
a 1:1 ratio, CD4 + T cells had a stronger negative effect on 
viability of IgH/c-myc + LCLs as compared to WT LCLs 
(Fig. 7b). Thus, CD4 + T cells affected IgH/c-myc + LCLs 
at both a “low dose” and “high dose” E/T ratio, while the 
viability of WT cells was strongly reduced only at “high 
dose” ratio. Notably, we could also see a reduced percent-
age of GFP + cells among living cells in co-culture, which 
was more profound at 5:1 E/T ratio (Fig. 7c). There were no 
effects of CD4 + T cells on LCL proliferation (Fig. 7d, Sup-
plementary Fig. 8) in co-culture or cell cycle distribution 
(Supplementary Fig. 8), neither on IgH/c-myc + LCLs nor on 
WT LCLs. Finally, there was no difference in CD4 + T cell 
effect on WT LCLs and IgH/c-myc + LCLs in expression of 
any EBV gene (EBNA2, LMP1, Cp or Qp promoter usage) 
or eBL markers (c-myc and bcl6) measured (Fig. 8).
Overall, our data imply that IgH/c-myc + LCLs are more 
susceptible to CD4 + T-cell-induced suppression of viability 
than WT LCLs.
Discussion
Evidence accumulates that CD4 + T cells are involved in the 
multi-step development of eBL, but the pathogenic role of 
CD4 + T cells remains enigmatic. Here, we unprecedently 
show that CD4 + T cells are present in primary eBL tumor 
tissues and that CD4 + T cells on the one hand kill pre-eBL 
cells in vitro and on the other hand can initiate crucial EBV 
Latency III to Latency I switch, which supposedly takes 
place early in eBL development, supporting the survival 
of EBV-infected pre-eBL cells by lowering their immune 
recognition. Furthermore, while we show that the mere 
presence of the characteristic IgH/c-myc translocation does 
not suffice to escape CD4 + T-cell-mediated killing in vitro, 
the CD4 + T-cell-mediated suppression of the Latency III 
program in vivo may allow cells harboring the IgH/c-myc 
translocation and additional mutations, to evade immune 
suppression and eventually proliferate by means of deregu-
lated c-myc activity, resulting in neoplasia.
A key finding of our study is the first-time demonstra-
tion of the presence of CD4 + T cells in primary eBL tis-
sue. They may either have been present at the emergence 
and propagation of the eBL cells or have infiltrated the 
neoplastic cells after having been attracted by antigen, or 
both. Since CD4 + T cells, depending on their subpopulation 
nature, exert either helping or suppressing/cytotoxic func-
tions, their impact on eBL cells or their precursors may be 
dichotomous as well.
Another key finding of our study is the demonstration that 
polyclonal activated CD4 + T cells suppress the viability and 
thereby the outgrowth of autologous pre-eBL cells. Reduced 
viability is further confirmed by reduction in the percentage 
of GFP + LCLs upon co-culture with CD4 + T cells, as GFP 
signal is downregulated in dying cells [39]. The exact mode 
of LCL cell death in our co-culture system is unclear. We 
did not observe changes in the relative proportion of apop-
totic cells over time, suggesting that alternative cell death 
pathways might be involved. CD4 + T-cells-mediated loss of 
EBNA2 expression in LCLs offers alternative explanation, 
as EBNA2 confers anti-apoptotic functions and its loss was 
shown to reduce the viability of LCLs [40]. These data indi-
cate that CD4 + T cells can exhibit suppressive or cytotoxic 
functions, in agreement with previous reports [26–29].
 Cancer Immunology, Immunotherapy
1 3
A third key finding in this study is our demonstration 
that CD4 + T cells can promote eBL emergence indirectly 
by inducing a switch to a more eBL-like phenotype in 
autologous EBV-infected pre-eBL cells resulting in immune 
escape. This is achieved, at least in part, through changes 
in expression of EBNA2, a transcription factor crucial for 
Latency III program, and bcl6, a key marker of eBL. Spe-
cifically, we show CD4 + T-cell-mediated reduction in the 
Cp promoter usage in LCLs and a consecutive reduction in 
EBNA2 expression, resulting in switching away from the 
dominant EBV Latency III program. As we did not see a 
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in our in vitro system was incomplete. This can be explained 
by lack of Tfh cells in our system, which can induce LMP1 
suppression in LCLs via production of IL-21 [32]. There-
fore, it is possible that during autologous CD4 + T cells/
pre-eBL cell interaction in vivo, in the presence of Tfh and 
IL-21, full Latency III to Latency I switch does take place. 
Furthermore, CD4 + T cells in our co-culture are activated 
using polyclonal anti-CD3/CD28 beads, rendering the effect 
of CD4 + T cells on LCLs independent on expression of 
HLA Class II molecules. As EBV latency [41] and c-myc 
activity [42] are known to affect expression of HLA Class 
II molecules on B cells, it is possible that the in vivo effect 
of relatively rare EBV-specific CD4 + T cells would differ 
from the effect observed in our in vitro system. On the other 
hand, polyclonal expansion mimics the effect of non-specif-
ically chronically stimulated CD4 + T cells, found in eBL-
associated chronic malaria [37], and obviates outgrowing 
EBV-specific CD4 + T cells lines, which would artificially 
skew the phenotype and antigen specificity of CD4 + T cell 
pool in our in vitro system.
While CD4 + T cells suppress outgrowth of “wild-
type” EBV-infected B cells, we needed to consider the 
possibility of rare EBV-infected B cells with IgH/c-myc 
translocation interacting with CD4 + T cells. Indeed, we 
hypothesized that EBV-infected B cells with IgH/c-myc 
translocation could switch to the alternative growth pro-
gram and survive the interaction with CD4 + T cells bet-
ter than wild-type EBV-infected B cells. Therefore, we 
established a novel IgH/c-myc translocation model. It 
offers a number of advantages over existing models rely-
ing on either c-myc overexpression or stable transfection 
with c-myc/IgH-containing plasmids [24, 25]. Firstly, we 
induce the translocation between endogenous c-myc and 
IgH genes, rather than another copy of the c-myc gene. 
Secondly, the existing epigenetic landscape is maintained. 
Thirdly, all relevant enhancers/regulators remain in place 
and at physiological distance from the c-myc gene. Finally, 
by placing the GFP tag into reciprocal translocation break-
point, rather than into the IgH/c-myc translocation of 
interest, we avoid introducing a strong promoter into the 
vicinity of the c-myc gene. Notably, the introduction of 
IgH/c-myc translocation did not induce significant changes 
in LCL cell phenotype, considered as surrogate for pre-
eBL. This is not surprising, as the literature suggests that 
EBV Latency III program is dominant over c-myc growth-
program [24, 25].
Our final key observation is that the mere presence of 
IgH/c-myc translocation does not protect autologous EBV-
infected B cells from CD4 + T-cell-mediated killing, but 
rather makes them more susceptible to it. This could be 
explained by the fact that IgH/c-myc + LCLs have a higher 
capacity for c-myc expression due to the presence of the 
translocation. In the absence of CD4 + T cells, EBNA2 
would maintain a moderate level of c-myc expression [20, 
43], suppress excessive c-myc expression from IgH/c-myc 
translocation [44] and provide some protection from c-myc-
mediated apoptosis [40] in both WT and IgH/c-myc + LCLs. 
In the presence of CD4 + T cells, which suppress EBNA2 
in LCLs, IgH/c-myc + LCLs become much more suscepti-
ble to apoptosis, as compared to WT LCLs, due to their 
capacity to express higher levels of c-myc from the translo-
cated chromosome. Cells that express high levels of c-myc 
would die before the mRNA analysis, which may explain 
the observed lack of changes in c-myc levels in IgH/c-
myc + LCLs in the presence of CD4 + T cells. Furthermore, 
LCLs already express high levels of c-myc and even small, 
undetectable changes in c-myc levels, may have strong physi-
ological effect [45]. Fully established eBL cells, in contrast, 
harbor additional mutations, such as ID3 and GNA13 [5], 
which may protect them from c-myc overexpression-induced 
apoptosis, while allowing the benefit from c-myc-mediated 
enhancement of proliferation. Several clones of EBNA2-
inducible/c-myc-inducible cell line were shown to survive 
and proliferate in a c-myc-dependent manner in the absence 
of EBNA2 after a several-week-long lag in proliferation 
[25], further supporting our hypothesis.
In conclusion, CD4 + T cells in eBL likely contribute 
to eBL pathogenesis by exhibiting a dichotomous impact 
through initiation of EBV Latency III to Latency I switch, 
thereby reducing EBV-infected B cell survival on the one 
hand, but increasing their survival by reducing their recog-
nition as EBV-infected by immune cells, possibly followed 
by outgrowth of IgH/c-myc-translocated cells on the other 
hand. Our model of B cells harboring the IgH/c-myc trans-
location will be instrumental for further studies on eBL 
pathogenesis. Since the method of its generation can easily 
Fig. 6  Effect of IgH/c-myc translocation on LCL phenotype. LCLs 
from four donors either with or without IgH/c-myc translocation were 
cultured at same density for 3 days and compared to assess the effect 
of translocation on LCL phenotype. Different symbols represent dif-
ferent conditions, while different colors represent different TMC 
donors. p values were calculated using paired t test. p > 0.05 not sig-
nificant (n.s.). For flow cytometry experiments, isotype staining was 
used to determine positive cells. Histogram overlays for one repre-
sentative donor can be found in Supplementary Fig.  8. WB images 
used for quantification can be found in Supplementary Fig. 6. a Pro-
liferation of LCLs was assessed by counting daily with hemocytome-
ter and by EdU incorporation assay using EdU Click-iT Flow Cytom-
etry Kit. b LCL viability was assessed using Zombie viability dye. 
c) Percentage of LCLs in different cell cycle stages was measured 
using EdU Click-iT Flow Cytometry Kit and FxCycle dye. d Total 
protein expression was assessed using Western blotting. Western blot 
image was quantified and normalized to β-actin as loading control. 
Shown are mean ± SD of normalized volume of corresponding band. 
e–f Gene expression was determined using qRT-PCR. Shown are 
mean ± SD of dCt values normalized to geometric means of TBP and 
YWHAZ. g, d Expression of surface co-stimulatory molecules (g) and 
EBV/eBL-associated markers (h) was assessed using flow cytometer. 
Shown are mean ± SD of mean fluorescent intensity (MFI)
◂










































































































































Percentage of LCLs in co-culture
5:1 T cell/LCL ratio
WT (co-culture)
IgH/c-myc+ (co-culture)







































































% of living cells

















ns ns ns ns ns **












5:1 T cell/LCL ratio





Fig. 7  Effect of CD4 + T cells on proliferation and viability of IgH/
c-myc + LCLs LCLs either with or without IgH/c-myc translocation 
were cultured for 9  days either alone or in co-culture with various 
ratios of expanded autologous CD4 + T cells activated using anti-
CD3/CD28 beads. At given time points, cells were harvested, stained 
and analyzed using flow cytometer. LCLs were pre-gated based 
on CD19 expression. Shown are mean ± SD of mean percentage 
of positive cells from three TMC donors. p values were calculated 
using two-way ANOVA with Tukey’s test for multiple comparisons. 
p > 0.05 not significant (n.s.), p < 0.1*, p < 0.01**, p < 0.001***, 
p < 0.0001****. Repeats with 1:1  T cell/LCL ratios can be found 
in Supplementary Fig.  7. a Mean percentage of LCLs in co-culture 
was determined by CD19 and CD4 staining. b Mean percentage of 
dead, apoptotic and living LCLs was measured using Annexin V stain 
and Zombie Viability stain. c Mean percentage of GFP + LCLs. d 
Mean percentage of EdU + LCLs was measured using Click-iT Flow 
Cytometry Kit













































































































































































Fig. 8  Effect of CD4 + T cells on gene expression in IgH/c-
myc + LCLs. LCLs either with or without IgH/c-myc translocation 
were cultured for 7  days either alone or in co-culture with vari-
ous ratios of expanded autologous CD4 + T cells activated using 
anti-CD3/CD28 beads. At given time points, cells were harvested 
and LCLs were isolated using CD19 + beads and autoMACS. Gene 
expression was determined using qRT-PCR. Shown are mean ± SD of 
dCt values normalized to geometric means of TBP and YWHAZ. Dif-
ferent symbols represent different conditions, while different colors 
represent different TMC donors. p values were calculated using two-
way ANOVA with Tukey’s test for multiple comparisons. p > 0.05 not 
significant (n.s.), p < 0.1*, p < 0.01**, p < 0.001***, p < 0.0001****
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be applied to engineer other clinically relevant transloca-
tions, it may thus serve to delineate novel therapies.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00262- 021- 03057-5.
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